{"id":39616,"date":"2023-01-31T15:50:57","date_gmt":"2023-01-31T15:50:57","guid":{"rendered":"https:\/\/www.elza-institute.com\/?p=39616"},"modified":"2024-07-15T09:20:16","modified_gmt":"2024-07-15T09:20:16","slug":"hafezi-discusses-advancing-cxl-with-osn","status":"publish","type":"post","link":"https:\/\/www.elza-institute.com\/pt\/hafezi-discusses-advancing-cxl-with-osn\/","title":{"rendered":"Farhad Hafezi fala sobre o avan\u00e7o do CXL com a OSN"},"content":{"rendered":"<p><span data-preserver-spaces=\"true\"><a href=\"https:\/\/www.elza-institute.com\/pt\/sobre\/farhad-hafezi\/\">Prof. Farhad Hafezi<\/a>, MD, PhD, FARVO \u00e9 o Diretor M\u00e9dico do The ELZA Institute, <a href=\"https:\/\/www.healio.com\/news\/ophthalmology\/20221129\/crosslinking-advancements-continue-in-us-europe\">foi recentemente entrevistado pela Ocular Surgery News (OSN)<\/a>onde falou sobre o avan\u00e7o da tecnologia CXL para o tratamento de ectasias da c\u00f3rnea como o ceratocone. A entrevista abordou tr\u00eas t\u00f3picos principais.<\/span><\/p>\n<h2><span data-preserver-spaces=\"true\">O protocolo sub400 que avan\u00e7a o CXL em c\u00f3rneas finas<\/span><\/h2>\n<p><span data-preserver-spaces=\"true\">Historicamente, os procedimentos de reticula\u00e7\u00e3o eram exclu\u00eddos de doentes com c\u00f3rneas mais finas do que 400 \u00b5m, para deixar uma regi\u00e3o de margem de seguran\u00e7a de ~70 \u00b5m sem reticula\u00e7\u00e3o na c\u00f3rnea. No entanto, como muitos doentes com doen\u00e7a avan\u00e7ada tinham c\u00f3rneas mais finas, muitos n\u00e3o foram tratados. Em 2007, o Prof. Hafezi e os seus colegas procuraram resolver este problema e introduziram riboflavina hipo-osmolar para inchar estas c\u00f3rneas finas at\u00e9 uma espessura superior a 400 \u00b5m antes de se iniciar a reticula\u00e7\u00e3o com irradia\u00e7\u00e3o UV. Mais recentemente, a equipa desenvolveu o protocolo sub400, que envolve a personaliza\u00e7\u00e3o da dura\u00e7\u00e3o da irradia\u00e7\u00e3o UV de acordo com a medi\u00e7\u00e3o da espessura da c\u00f3rnea de cada doente. Hafezi disse \u00e0 OSN que este protocolo \"modifica a dura\u00e7\u00e3o da irradia\u00e7\u00e3o UV a 3 mW\/cm\u00b2 para atingir a profundidade desejada necess\u00e1ria para reticular a c\u00f3rnea de cada doente e deixar uma margem de seguran\u00e7a de 70 \u00b5m\". Hafezi e os seus colaboradores foram capazes de modelar todos os componentes da rea\u00e7\u00e3o fotoqu\u00edmica do CXL: riboflavina, tecido da c\u00f3rnea, disponibilidade de oxig\u00e9nio e intensidade e dura\u00e7\u00e3o da luz UV.<\/span><\/p>\n<h2><span data-preserver-spaces=\"true\">Flu\u00eancia e intensidade mais elevadas<\/span><\/h2>\n<p><span data-preserver-spaces=\"true\">A Ocular Surgery News foi tamb\u00e9m informada de que o seu grupo de investiga\u00e7\u00e3o est\u00e1 tamb\u00e9m a explorar formas de fazer avan\u00e7ar a tecnologia e os tratamentos CXL, principalmente tornando-os mais r\u00e1pidos atrav\u00e9s da utiliza\u00e7\u00e3o de intensidades de luz UV mais elevadas. Gra\u00e7as \u00e0 modela\u00e7\u00e3o das intera\u00e7\u00f5es UV-riboflavina-c\u00f3rnea e a um programa de valida\u00e7\u00e3o cl\u00ednica, o protocolo sub400 atualizado da equipa inclui agora uma flu\u00eancia nitidamente mais elevada e uma intensidade de reticula\u00e7\u00e3o acelerada de 9 mW\/cm\u00b2. Isto permitir\u00e1 tempos de irradia\u00e7\u00e3o UV mais curtos e personalizados do protocolo sub400, tanto para m\u00e9dicos como para pacientes.<\/span><\/p>\n<h2><span data-preserver-spaces=\"true\">L\u00e2mpada de fenda CXL<\/span><\/h2>\n<p><span data-preserver-spaces=\"true\">Hafezi disse \u00e0 OSN que ele e a sua equipa est\u00e3o a explorar novas vias para a tecnologia. Por exemplo, a realiza\u00e7\u00e3o de procedimentos de CXL com o doente sentado na vertical, \u00e0 luz da l\u00e2mpada de fenda, em vez de estar deitado. Para provar a validade desta abordagem, a equipa examinou a profundidade da linha de demarca\u00e7\u00e3o em 23 olhos que foram submetidos a cross-linking na l\u00e2mpada de fenda e comparou os resultados com a literatura existente. Hafezi explicou \u00e0 OSN que os resultados n\u00e3o mostraram \"nenhuma diferen\u00e7a na profundidade do efeito do cross-linking\". Esta \u00e9 uma descoberta importante que apoia o conceito de que o CXL \u00e0 l\u00e2mpada de fenda (num consult\u00f3rio) \u00e9 t\u00e3o eficaz como o CXL realizado numa posi\u00e7\u00e3o deitada (normalmente num bloco operat\u00f3rio).<\/span><\/p>\n<h2><span data-preserver-spaces=\"true\">Conclus\u00e3o<\/span><\/h2>\n<p><span data-preserver-spaces=\"true\">Hafezi disse \u00e0 OSN que, atrav\u00e9s do seu trabalho, pretendem melhorar a qualidade dos cuidados que os doentes recebem e tornar os procedimentos CXL mais r\u00e1pidos e mais convenientes, acrescentando: \"Estamos sempre \u00e0 procura de formas de tornar os nossos procedimentos melhores e mais eficazes e de proporcionar o mais elevado n\u00edvel de cuidados aos nossos doentes.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/rfs-Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN.pdf\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-39617 size-large\" src=\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN-700x1024.png\" alt=\"Farhad Hafezi fala sobre o avan\u00e7o do CXL com a OSN\" width=\"700\" height=\"1024\" srcset=\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN-700x1024.png 700w, https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN-205x300.png 205w, https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN-768x1123.png 768w, https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN-8x12.png 8w, https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN.png 870w\" sizes=\"(max-width: 700px) 100vw, 700px\" \/><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>O Prof. Farhad Hafezi, MD, PhD, FARVO \u00e9 o Diretor M\u00e9dico do Instituto ELZA, foi recentemente entrevistado pela Ocular Surgery News (OSN), onde falou sobre o avan\u00e7o da tecnologia CXL para o tratamento de ectasias da c\u00f3rnea como o ceratocone. A entrevista abordou tr\u00eas t\u00f3picos principais.<\/p>","protected":false},"author":4,"featured_media":39619,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[214,96,467],"tags":[506,209,132,125,275,130,100,123,353,119,122,424],"class_list":["post-39616","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-farhad-hafezi","category-popular-press","category-top-10","tag-accelerated","tag-basic-research","tag-biomechanics","tag-cornea","tag-corneal-biomechanics","tag-cross-linking","tag-cxl","tag-keratoconus","tag-sub400","tag-thin-corneas","tag-translational-research","tag-ultra-thin"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Farhad Hafezi Discusses Advancing CXL with OSN - The ELZA Institute<\/title>\n<meta name=\"description\" content=\"OSN interviewed Farhad Hafezi about his work in advancing CXL with the sub400 thin cornea protocol, better accelerated CXL, and slit lamp CXL\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.elza-institute.com\/pt\/hafezi-discusses-advancing-cxl-with-osn\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Farhad Hafezi Discusses Advancing CXL with OSN - The ELZA Institute\" \/>\n<meta property=\"og:description\" content=\"OSN interviewed Farhad Hafezi about his work in advancing CXL with the sub400 thin cornea protocol, better accelerated CXL, and slit lamp CXL\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.elza-institute.com\/pt\/hafezi-discusses-advancing-cxl-with-osn\/\" \/>\n<meta property=\"og:site_name\" content=\"The ELZA Institute\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ELZA.Institute\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-31T15:50:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-15T09:20:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/COVER-IMAGE-Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Mark Hillen\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mark Hillen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/\"},\"author\":{\"name\":\"Mark Hillen\",\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15\"},\"headline\":\"Farhad Hafezi Discusses Advancing CXL with OSN\",\"datePublished\":\"2023-01-31T15:50:57+00:00\",\"dateModified\":\"2024-07-15T09:20:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/\"},\"wordCount\":491,\"publisher\":{\"@id\":\"https:\/\/www.elza-institute.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/COVER-IMAGE-Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN.jpg\",\"keywords\":[\"accelerated\",\"Basic Research\",\"Biomechanics\",\"Cornea\",\"corneal biomechanics\",\"Cross-Linking\",\"CXL\",\"Keratoconus\",\"sub400\",\"Thin corneas\",\"Translational Research\",\"ultra-thin\"],\"articleSection\":[\"Farhad Hafezi\",\"Popular press\",\"Top 10\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/\",\"url\":\"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/\",\"name\":\"Farhad Hafezi Discusses Advancing CXL with OSN - The ELZA Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.elza-institute.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/COVER-IMAGE-Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN.jpg\",\"datePublished\":\"2023-01-31T15:50:57+00:00\",\"dateModified\":\"2024-07-15T09:20:16+00:00\",\"description\":\"OSN interviewed Farhad Hafezi about his work in advancing CXL with the sub400 thin cornea protocol, better accelerated CXL, and slit lamp CXL\",\"breadcrumb\":{\"@id\":\"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#primaryimage\",\"url\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/COVER-IMAGE-Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN.jpg\",\"contentUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/COVER-IMAGE-Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN.jpg\",\"width\":1200,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.elza-institute.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Farhad Hafezi\",\"item\":\"https:\/\/www.elza-institute.com\/farhad-hafezi\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Farhad Hafezi Discusses Advancing CXL with OSN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.elza-institute.com\/#website\",\"url\":\"https:\/\/www.elza-institute.com\/\",\"name\":\"The ELZA Institute\",\"description\":\"Swiss EyeCare at its finest\",\"publisher\":{\"@id\":\"https:\/\/www.elza-institute.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.elza-institute.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.elza-institute.com\/#organization\",\"name\":\"The ELZA Institute\",\"url\":\"https:\/\/www.elza-institute.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg\",\"contentUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg\",\"width\":1181,\"height\":453,\"caption\":\"The ELZA Institute\"},\"image\":{\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ELZA.Institute\/\",\"https:\/\/x.com\/ELZA_Institute\",\"https:\/\/www.linkedin.com\/company\/elza-institute?trk=top_nav_home\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15\",\"name\":\"Mark Hillen\",\"url\":\"https:\/\/www.elza-institute.com\/pt\/author\/markhillen\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Farhad Hafezi fala sobre o avan\u00e7o do CXL com a OSN - O Instituto ELZA","description":"A OSN entrevistou Farhad Hafezi sobre o seu trabalho no avan\u00e7o do CXL com o protocolo de c\u00f3rnea fina sub400, melhor CXL acelerado e CXL com l\u00e2mpada de fenda","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.elza-institute.com\/pt\/hafezi-discusses-advancing-cxl-with-osn\/","og_locale":"pt_PT","og_type":"article","og_title":"Farhad Hafezi Discusses Advancing CXL with OSN - The ELZA Institute","og_description":"OSN interviewed Farhad Hafezi about his work in advancing CXL with the sub400 thin cornea protocol, better accelerated CXL, and slit lamp CXL","og_url":"https:\/\/www.elza-institute.com\/pt\/hafezi-discusses-advancing-cxl-with-osn\/","og_site_name":"The ELZA Institute","article_publisher":"https:\/\/www.facebook.com\/ELZA.Institute\/","article_published_time":"2023-01-31T15:50:57+00:00","article_modified_time":"2024-07-15T09:20:16+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/COVER-IMAGE-Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN.jpg","type":"image\/jpeg"}],"author":"Mark Hillen","twitter_misc":{"Escrito por":"Mark Hillen","Tempo estimado de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#article","isPartOf":{"@id":"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/"},"author":{"name":"Mark Hillen","@id":"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15"},"headline":"Farhad Hafezi Discusses Advancing CXL with OSN","datePublished":"2023-01-31T15:50:57+00:00","dateModified":"2024-07-15T09:20:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/"},"wordCount":491,"publisher":{"@id":"https:\/\/www.elza-institute.com\/#organization"},"image":{"@id":"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#primaryimage"},"thumbnailUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/COVER-IMAGE-Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN.jpg","keywords":["accelerated","Basic Research","Biomechanics","Cornea","corneal biomechanics","Cross-Linking","CXL","Keratoconus","sub400","Thin corneas","Translational Research","ultra-thin"],"articleSection":["Farhad Hafezi","Popular press","Top 10"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/","url":"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/","name":"Farhad Hafezi fala sobre o avan\u00e7o do CXL com a OSN - O Instituto ELZA","isPartOf":{"@id":"https:\/\/www.elza-institute.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#primaryimage"},"image":{"@id":"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#primaryimage"},"thumbnailUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/COVER-IMAGE-Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN.jpg","datePublished":"2023-01-31T15:50:57+00:00","dateModified":"2024-07-15T09:20:16+00:00","description":"A OSN entrevistou Farhad Hafezi sobre o seu trabalho no avan\u00e7o do CXL com o protocolo de c\u00f3rnea fina sub400, melhor CXL acelerado e CXL com l\u00e2mpada de fenda","breadcrumb":{"@id":"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/"]}]},{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#primaryimage","url":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/COVER-IMAGE-Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN.jpg","contentUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2023\/01\/COVER-IMAGE-Farhad-Hafezi-Discusses-Advancing-CXL-with-OSN.jpg","width":1200,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/www.elza-institute.com\/hafezi-discusses-advancing-cxl-with-osn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.elza-institute.com\/"},{"@type":"ListItem","position":2,"name":"Farhad Hafezi","item":"https:\/\/www.elza-institute.com\/farhad-hafezi\/"},{"@type":"ListItem","position":3,"name":"Farhad Hafezi Discusses Advancing CXL with OSN"}]},{"@type":"WebSite","@id":"https:\/\/www.elza-institute.com\/#website","url":"https:\/\/www.elza-institute.com\/","name":"O Instituto ELZA","description":"Swiss EyeCare no seu melhor","publisher":{"@id":"https:\/\/www.elza-institute.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.elza-institute.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/www.elza-institute.com\/#organization","name":"O Instituto ELZA","url":"https:\/\/www.elza-institute.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg","contentUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg","width":1181,"height":453,"caption":"The ELZA Institute"},"image":{"@id":"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ELZA.Institute\/","https:\/\/x.com\/ELZA_Institute","https:\/\/www.linkedin.com\/company\/elza-institute?trk=top_nav_home"]},{"@type":"Person","@id":"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15","name":"Mark Hillen","url":"https:\/\/www.elza-institute.com\/pt\/author\/markhillen\/"}]}},"_links":{"self":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/posts\/39616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/comments?post=39616"}],"version-history":[{"count":0,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/posts\/39616\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/media\/39619"}],"wp:attachment":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/media?parent=39616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/categories?post=39616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/tags?post=39616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}